DEUTSCHE BANK AG\ - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$836,420
+69.4%
452,119
+1.7%
0.00%
Q4 2022$493,639
-58.4%
444,720
-12.4%
0.00%
-100.0%
Q3 2022$1,187,000
+356.5%
507,406
+491.8%
0.00%
Q2 2022$260,000
-52.6%
85,735
+6.0%
0.00%
Q1 2022$549,000
+30.1%
80,857
+59.8%
0.00%
Q4 2021$422,000
+199.3%
50,592
+166.9%
0.00%
Q3 2021$141,000
+6.0%
18,957
-3.1%
0.00%
Q2 2021$133,000
+15.7%
19,571
+74.5%
0.00%
Q1 2021$115,000
+33.7%
11,216
-8.5%
0.00%
Q4 2020$86,000
+19.4%
12,257
+39.6%
0.00%
Q3 2020$72,000
+30.9%
8,782
+10.6%
0.00%
Q2 2020$55,000
+71.9%
7,943
+18.7%
0.00%
Q1 2020$32,000
-90.8%
6,691
-83.3%
0.00%
Q4 2019$348,000
+25.6%
40,070
-52.0%
0.00%
Q3 2019$277,000
-51.3%
83,562
-27.4%
0.00%
Q2 2019$569,000
-43.6%
115,151
-29.3%
0.00%
-100.0%
Q1 2019$1,008,000
+99.2%
162,852
+8.4%
0.00%
Q4 2018$506,000
-63.1%
150,295
-28.8%
0.00%
Q3 2018$1,372,000
+128.7%
211,191
+169.6%
0.00%
Q2 2018$600,000
+2.6%
78,323
+198.5%
0.00%
Q1 2018$585,000
+40.6%
26,236
-19.7%
0.00%
Q4 2017$416,000
+28.8%
32,676
+56.6%
0.00%
Q3 2017$323,000
+70.9%
20,871
+53.0%
0.00%
Q2 2017$189,000
+6.8%
13,638
+68.5%
0.00%
Q1 2017$177,0008,0960.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
TRV GP II, LLC 9,200,349$64,402,00044.86%
TRV GP III, LLC 3,048,780$21,342,0001.83%
SILVERARC CAPITAL MANAGEMENT, LLC 406,665$2,847,0001.65%
Sofinnova Investments, Inc. 925,280$6,477,0000.39%
Omega Fund Management, LLC 334,965$2,345,0000.35%
Yorktown Management & Research Co Inc 49,200$344,0000.31%
Woodline Partners LP 940,902$6,586,0000.18%
HUSSMAN STRATEGIC ADVISORS, INC. 51,000$357,0000.09%
HORIZON FINANCIAL SERVICES, LLC 12,005$84,0000.08%
Gyon Technologies Capital Management, LP 26,893$188,0000.06%
View complete list of JOUNCE THERAPEUTICS INC shareholders